MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woynarowski, J. M.
Right arrow Articles by Juniewicz, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woynarowski, J. M.
Right arrow Articles by Juniewicz, P.

Vol. 54, Issue 5, 770-777, November 1998

Sequence- and Region-Specificity of Oxaliplatin Adducts in Naked and Cellular DNA

Jan M. Woynarowski, William G. Chapman, Cheryl Napier, Maryanne C. S. Herzig, and Paul Juniewicz

Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas 78245 (J.M.W., W.G.C., C.N., M.C.S.H.), and Sanofi Research, Malvern, Pennsylvania 19355 (P.J.)

Oxaliplatin is a clinical anticancer drug with a pharmacological profile distinct from that of cisplatin. Our studies compared site- and region-specificity of lesions induced by oxaliplatin and cisplatin in naked and intracellular DNA, respectively. Oxaliplatin adducts in naked Simian virus 40 (SV40 DNA) were mapped by repetitive primer extension. The sites of oxaliplatin adducts were nearly identical to the sites of cisplatin adducts and were focused in G clusters and GNG motifs probably reflecting intrastrand cross-links. Although alkaline agarose electrophoresis of specific SV40 fragments showed that oxaliplatin formed interstrand cross-links, the levels of this lesion type were low. Drug-induced lesions in discrete loci of cellular DNA were assessed by the polymerase chain reaction stop assay in human tumor A2780 cells. Oxaliplatin at 200 µM induced ~1300, ~1500, ~800, and ~300 lesions/106 bp in the human beta -globin, c-myc, and HPRT genes and in mitochondrial DNA, respectively. Cisplatin formed two to six times more lesions in the same regions. For both drugs, lesion frequencies seem to parallel the density of drug-binding motifs in the nuclear regions, whereas mitochondrial DNA was disproportionately less affected. Despite less potent induction of DNA lesions, oxaliplatin was more cytotoxic than cisplatin against A2780 cells. Because our findings clearly demonstrate that oxaliplatin forms covalent adducts with a similar sequence- and region-specificity to that of cisplatin, other properties of oxaliplatin adducts, factors other than DNA binding, or both determine the unique features of the mechanism of action of oxaliplatin.

Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Biophys. JHome page
J. Malina, O. Novakova, M. Vojtiskova, G. Natile, and V. Brabec
Conformation of DNA GG Intrastrand Cross-Link of Antitumor Oxaliplatin and Its Enantiomeric Analog
Biophys. J., December 1, 2007; 93(11): 3950 - 3962.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. L. Spunt, B. B. Freeman III, C. A. Billups, V. McPherson, R. B. Khan, C. B. Pratt, and C. F. Stewart
Phase I Clinical Trial of Oxaliplatin in Children and Adolescents With Refractory Solid Tumors
J. Clin. Oncol., June 1, 2007; 25(16): 2274 - 2280.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Zhang, K. S. Lovejoy, J. E. Shima, L. L. Lagpacan, Y. Shu, A. Lapuk, Y. Chen, T. Komori, J. W. Gray, X. Chen, et al.
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity.
Cancer Res., September 1, 2006; 66(17): 8847 - 8857.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Voland, A. Bord, A. Peleraux, G. Penarier, D. Carriere, S. Galiegue, E. Cvitkovic, O. Jbilo, and P. Casellas
Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells.
Mol. Cancer Ther., September 1, 2006; 5(9): 2149 - 2157.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. M. Goldberg, D. J. Sargent, R. F. Morton, C. S. Fuchs, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, H. C. Pitot, and S. Alberts
Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial
J. Clin. Oncol., July 20, 2006; 24(21): 3347 - 3353.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. H. Park, J. Y. Sung, S.-H. Han, J. H. Baek, J. H. Oh, S.-M. Bang, E. K. Cho, D. B. Shin, and J. H. Lee
Oxaliplatin, Folinic Acid and 5-Fluorouracil (FOLFOX-4) Combination Chemotherapy as Second-line Treatment in Advanced Colorectal Cancer Patients with Irinotecan Failure: A Korean Single-center Experience
Jpn. J. Clin. Oncol., September 1, 2005; 35(9): 531 - 535.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Venook
Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer
Oncologist, April 1, 2005; 10(4): 250 - 261.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Hector, C. W. Porter, D. L. Kramer, K. Clark, J. Prey, N. Kisiel, P. Diegelman, Y. Chen, and L. Pendyala
Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase
Mol. Cancer Ther., July 1, 2004; 3(7): 813 - 822.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. I. Wu, J. A. Brown, M. J. Dorie, L. Lazzeroni, and J. M. Brown
Genome-Wide Identification of Genes Conferring Resistance to the Anticancer Agents Cisplatin, Oxaliplatin, and Mitomycin C
Cancer Res., June 1, 2004; 64(11): 3940 - 3948.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. M. Goldberg, D. J. Sargent, R. F. Morton, C. S. Fuchs, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, H. C. Pitot, and S. R. Alberts
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
J. Clin. Oncol., January 1, 2004; 22(1): 23 - 30.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. H. Takimoto, S. C. Remick, S. Sharma, S. Mani, R. K. Ramanathan, J. Doroshow, A. Hamilton, D. Mulkerin, M. Graham, G. F. Lockwood, et al.
Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study
J. Clin. Oncol., July 15, 2003; 21(14): 2664 - 2672.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic
Cellular and Molecular Pharmacology of Oxaliplatin
Mol. Cancer Ther., January 1, 2002; 1(3): 227 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. M. Woynarowski, S. Faivre, M. C.S. Herzig, B. Arnett, W. G. Chapman, A. V. Trevino, E. Raymond, S. G. Chaney, A. Vaisman, M. Varchenko, et al.
Oxaliplatin-Induced Damage of Cellular DNA
Mol. Pharmacol., November 1, 2000; 58(5): 920 - 927.
[Abstract] [Full Text]

Home page
 JNMHome page
T. A.D. Smith, N. R. Maisey, J. C. Titley, L. E. Jackson, M. O. Leach, and S. M. Ronen
Treatment of SW620 Cells with Tomudex and Oxaliplatin Induces Changes in 2-Deoxy-D-Glucose Incorporation Associated with Modifications in Glucose Transport
J. Nucl. Med., October 1, 2000; 41(10): 1753 - 1759.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Vaisman and S. G. Chaney
The Efficiency and Fidelity of Translesion Synthesis past Cisplatin and Oxaliplatin GpG Adducts by Human DNA Polymerase beta
J. Biol. Chem., April 21, 2000; 275(17): 13017 - 13025.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
E. D. Scheeff, J. M. Briggs, and S. B. Howell
Molecular Modeling of the Intrastrand Guanine-Guanine DNA Adducts Produced by Cisplatin and Oxaliplatin
Mol. Pharmacol., September 1, 1999; 56(3): 633 - 643.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
J. Kasparkova, N. Farrell, and V. Brabec
Sequence Specificity, Conformation, and Recognition by HMG1 Protein of Major DNA Interstrand Cross-links of Antitumor Dinuclear Platinum Complexes
J. Biol. Chem., May 19, 2000; 275(21): 15789 - 15798.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Vaisman, M. W. Warren, and S. G. Chaney
The Effect of DNA Structure on the Catalytic Efficiency and Fidelity of Human DNA Polymerase beta on Templates with Platinum-DNA Adducts
J. Biol. Chem., May 25, 2001; 276(22): 18999 - 19005.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. M. Woynarowski, A. V. Trevino, K. A. Rodriguez, S. C. Hardies, and C. J. Benham
AT-rich Islands in Genomic DNA as a Novel Target for AT-specific DNA-reactive Antitumor Drugs
J. Biol. Chem., October 26, 2001; 276(44): 40555 - 40566.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics